CDXI logo

Cardax, Inc. Stock Price

OTCPK:CDXI Community·US$82.0 Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

CDXI Share Price Performance

US$0.0001
0.00 (0.00%)
US$0.0001
0.00 (0.00%)
Price US$0.0001

CDXI Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Low risk with weak fundamentals.

3 Risks
0 Rewards

Cardax, Inc. Key Details

US$500.7k

Revenue

US$171.5k

Cost of Revenue

US$329.2k

Gross Profit

US$5.8m

Other Expenses

-US$5.4m

Earnings

Last Reported Earnings
Mar 31, 2021
Next Reporting Earnings
n/a
0
0%
0%
0%
View Full Analysis

About CDXI

Founded
n/a
Employees
n/a
CEO
David Watumull
WebsiteView website
www.cardaxpharma.com

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

Recent CDXI News & Updates

Recent updates

No updates